



April 15, 2010

Dear Colleague,

Pasadena Veterinary Specialists is involved in three clinical studies conducted by AB Science. The studies investigate the efficacy and safety of the following:

1. Masitinib as a single agent or in combination with doxorubicin in the treatment of dogs with T-cell lymphoma;
2. Masitinib as a single agent or in combination with doxorubicin in the treatment of splenic hemangiosarcoma post-splenectomy;
3. Masitinib in combination with vinblastine in the treatment of advanced malignant tumor that is measurable and amenable to core biopsy.

Masitinib has already been approved by The European Medicines Agency (EMA) for the treatment of grade II and grade III mast cell tumors in dogs. It works by selectively inhibiting membrane receptors, including c-kit and platelet-derived growth factor receptors (PDGFR), and intracellular receptors, including Lyn tyrosine kinase enzymes.

Since the current treatments for T-cell lymphoma, splenic hemangiosarcoma and advanced malignant tumor are limited, it is important to continue researching other treatment modalities and better the life of our beloved canines. We at Pasadena Veterinary Specialists would greatly appreciate if you refer dogs with the fore mentioned neoplastic diseases to us for potential enrollment into the studies.

Main inclusion criteria:

Dogs suffering from T-cell lymphoma splenic hemangiosarcoma (post splenectomy), or advanced malignant tumor, naïve of treatment, with adequate organ function.

Main exclusion criteria:

Dogs less than 6 months of age or weighing less than 3.5 kg, with cardiac insufficiency, evidence of gastric bleeding, other serious disease or prior history of kidney disease.

Please feel free to contact us if you may have further questions or comments. We hope to hear from you soon.

Sincerely,

Jocelyn Mott, DVM, Dipl. ACVIM (Small Animal Internal Medicine)

Vivian Yau, DVM, Practice Limited to Small Animal Internal Medicine